Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Menin inhibitors seek to debut as newest targeted therapy for leukaemia

Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias.
  1. Ken Garber
    View author publications

    You can also search for this author in PubMed  Google Scholar

An important new class of drugs for acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) could soon secure FDA approval. The agency should decide on Syndax’s first-in-class menin inhibitor revumenib by late September. At least seven small-molecule inhibitors of this scaffold protein are in clinical trials (Table 1). These drugs look to be effective in at least two genetic subsets of leukaemia.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 567-569 (2024)

doi: https://doi.org/10.1038/d41573-024-00106-3

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links